4 completed, 1 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Processa Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors PCS6422 and capecitabine - Advanced Cancer, Refractory Cancer | Phase 1 | Completed | Processa Pharmaceuticals | 23 | 2021-06-18 | 2024-10-10 |
| Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects PCS499, Trental - Healthy | Phase 1 | Completed | Processa Pharmaceuticals | 18 | 2018-02-26 | 2019-02-12 |
| RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer RX-3117 - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Processa Pharmaceuticals | 46 | 2017-10-02 | 2023-12-06 |
| Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies RX-3117 - Solid Tumor, Metastatic Bladder Cancer | Phase 1 / Phase 2 | Completed | Processa Pharmaceuticals | 127 | 2013-12-01 | 2023-12-06 |
| Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy HT-100 - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Terminated | Processa Pharmaceuticals | 17 | 2013-05-01 | 2020-09-03 |
Neoplasms (2) · Muscular Dystrophy, Duchenne (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
fluorocyclopentenylcytosine (2) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Pentoxifylline (1)
United States (4) · United Kingdom (1)
Ely Benaim, MD (2) · Diana M Escolar, MD (1) · Sharan Sidhu, MBChB (1) · Sian Bigora, Pharm. D (1)